Drug Trial Radar · NCT07471139
SWITCH: Apixaban vs Vitamin K in HM3
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
460
Planned (sponsor's estimate)
Start
Oct 15, 2026
Primary completion
Aug 2029
Study completion Oct 2029
Sponsor
- Lead sponsor
- Columbia UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to learn the safety and efficacy of a new anticoagulant therapy with apixaban as compared to warfarin to prevent thrombotic events while protecting from bleeding complications in patients with advanced heart failure who are chronically supported by a HeartMate 3 Left Ventricular Assist Device for 3 months.
Conditions
- LVAD (Left Ventricular Assist Device) Thrombosis
- Heart Failure
- Bleeding
- Thrombosis; Artery
- Stroke
- Heart Transplant
Interventions
WarfarinDrug
Warfarin dose titrated for an International Normalized Ratio (INR) \>= 1.8
ApixabanDrug
Apixaban 5 mg bid (twice a day)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Survival free of major hemocompatibility related adverse eventTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Columbia University Irving Medical Center
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.